Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3329-3334

  Krishna, Rajesh ^a,b   De Jong, Gary ^b   Mayer, Lawrence D ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Doxorubicin; Latency; Multidrug resistance; P glycoprotein; PSC 833

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; VALSPODAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG SENSITIVITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CYCLOSPORINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA P388; MICE; TIME FACTORS; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0030830942     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Alaoui-Jamali MA, Schecter RL, Rustum YM, Centurioni MG, Lehnert S, and Batist G: in vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933. J Pharmacol Exp Ther 264: 1299-1304, 1993.
2. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, and Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1988.
3. Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW, and Cohen D: Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7: 603-610, 1995.
4. Boesch D, and Loor F: Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after expire to resistance-modifying agents. Anti-Cancer Drugs 5: 229-238, 1994.
5. de Jong G, Gelmon K, Bally MB, Goldie J, and Mayer LD: Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15: 911-916, 1995.
6. Fan D, Beltran PJ, and O£Brian CA: Reversal of multidrug resistance. In: Kellen JA (ed) Reversal of multidrug resistance in cancer. CRC Press, Boca Raton, Ann Arbor, London, Tokyo, p. 93, 1994.
7. Goldstein LJ: Clinical reversal of drug resistance. Current Problems in Cancer 19: 65-124, 1995.
8. Jiang XR, Kelsey SM, Wu YL, and Newland AC: Circumvention of P-glycoprotein-mediated drug resistance in human leukemic: cells by non-immunosuppressive cyclosporin D analog, PSC 833. Br J Haematol 90: 375-383, 1995.
9. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P, and Hiestand PC: SDZ PSC 833, a non-immunosuppressive cyclosporin: its potency in overcoming P glycoprotein mediated multidrug resistance of murine leukemia. Int J Cancer 50: 593-597, 1992.
10. Mayer LD, and Hartley D: Identification of two distinct intracellular verapamil binding pools that contribute to the reversal of multidrug resistance in P388/ADR cells. Proc Amer Ass Can Res 36: 341, 1995.
11. Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, and Halsey J: Clinical reversal of multidrug resistance. Cancer Treatment Res 73: 149-165, 1994.
12. Perez V, Pierre A, Leonce S, Anstett M, and Atassi G: Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin. Anticancer Res 13: 985-990, 1993.
13. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, and Bleehen NM: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618, 1996.
14. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, and O'Brien JP: Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13: 1958-1965, 1995.